Gentry v. Bioverativ US LLC

CourtDistrict Court, D. South Carolina
DecidedAugust 13, 2019
Docket2:19-cv-00873
StatusUnknown

This text of Gentry v. Bioverativ US LLC (Gentry v. Bioverativ US LLC) is published on Counsel Stack Legal Research, covering District Court, D. South Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gentry v. Bioverativ US LLC, (D.S.C. 2019).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION JOHN GENTRY, ) ) Civil Action No. 2:19-00873-MBS Plaintiff, ) ) v. ) OPINION AND ORDER ) BIOVERATIV U.S. LLC, ) ) Defendant. ) ____________________________________) Plaintiff John Gentry (“Plaintiff”) brought the within action against Defendant Bioverativ U.S. LLC (“Defendant”) in the Court of Common Pleas for Berkeley County, South Carolina. The action was removed to this court on March 22, 2019. Plaintiff claims Defendant wrongfully terminated his employment in violation of public policy. Plaintiff also alleges the termination gives rise to a violation of the South Carolina Payment of Wages Act as well as claims of promissory estoppel, conversion, and defamation. This matter is before the court on Defendant’s motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), filed on March 29, 2019. ECF No. 5. Plaintiff filed an opposition to Defendant’s motion on April 18, 2019, ECF No. 10, to which Defendant filed a reply on April 25, 2019, ECF No. 11. The court exercises subject matter jurisdiction pursuant to 28 U.S.C. § 1332. FACTUAL BACKGROUND Plaintiff began his employment with Defendant’s predecessor, Biogen, on September 3, 2013, as the company’s hemophilia account executive. ECF No. 1-1 at ¶¶ 7, 9. Defendant is a company that specializes in the development and sale of pharmaceutical products to treat hemophilia and other blood disorders, ECF No. 5-1 at 1, and was formed from Biogen’s hemophilia division in February 2017, ECF No. 1-1 at ¶ 8. In early January 2018, Plaintiff learned that Sanofi Genzyme had purchased or was planning to purchase Defendant for approximately $11.6 billion. Id. at ¶¶ 2, 12, 13. On February 22, 2018, Plaintiff received a telephone call from Jim Snider, Defendant’s vice president of sales. ECF No. 1-1 at ¶¶ 11, 15. Mr. Snider told Plaintiff that a physician had

complained that Plaintiff had “sent a link to a press release, letting everyone know about the publishing of a study for an off-label use of a product sold by Plaintiff’s former employer.” Id. at ¶ 17. Mr. Snider told Plaintiff that “by sending the link, Plaintiff’s act constituted the promotion of off-label use of the medicine,” a compliance violation, and informed Plaintiff that he was fired as a result. Id. at ¶¶ 11, 15, 20. Plaintiff was terminated February 22, 2018, two weeks prior to the anticipated Sanofi Genzyme acquisition of Defendant. Id. at ¶ 11. Plaintiff asserts that Titles 33 and 35 of the South Carolina Code require business entities to “engage in mergers and acquisitions in such a manner that a shareholder and employee with stake in a company is entitled a complete transfer of rights upon merger and acquisition.” ECF

No. 1-1at ¶ 37. He alleges that with the acquisition he would have received substantial “stock rights,” and that as a result of his termination “he suffered significant stock and value losses”; he was “also denied payment for his 2017 Fourth Quarter performance commissions/bonus in excess of $10,000.” Id. at ¶¶ 29, 34. Plaintiff asserts that he “had a clean employment record” and “no compliance violations.” Id. at ¶¶ 21, 22. He alleges that “Defendant itself released and disseminated the same information,” which was set forth in the public press release, and that “Defendant falsely accused Plaintiff of promoting off-label use of medicine as pretextual grounds to terminate Plaintiff’s employment.” Id. at ¶ 25. LEGAL STANDARD Defendant moves to dismiss the entire complaint under Rule 12(b)(6). A Rule 12(b)(6) motion to dismiss for failure to state a claim upon which relief can be granted tests the legal sufficiency of a complaint. Schatz v. Rosenberg, 943 F.2d 455, 489 (4th Cir. 1991). While the complaint need not be minutely detailed, it must provide enough factual details to put the

opposing party on fair notice of the claim and the grounds upon which it rests. Bell Atl. Corp. v. Twombly, 550 U.S 544, 555 (2007) (citing Conley v. Gibson, 355 U.S. 41, 47 (1957)). Additionally, a complaint must contain factual content that allows the court to reasonably infer the defendant is liable for the alleged misconduct. Ashcroft v. Iqbal, 556 U.S 662, 678 (2009) (“A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.”). “Facts that are ‘merely consistent with’ liability do not establish a plausible claim to relief.” United States ex rel. Nathan v. Takeda Pharms. N. Am., Inc., 707 F.3d 451, 455 (4th Cir. 2013) (quoting Iqbal, 556 U.S. at 678). See 5 C. Wright & A. Miller, Federal Practice and Procedure § 1216,

pp. 235–236 (3d ed. 2004) (“[T]he pleading must contain something more . . . than . . . a statement of facts that merely creates a suspicion [of] a legally cognizable right of action”). The court must accept the allegations in the complaint as true and draw all reasonable factual inferences in favor of the party opposing the motion. Iqbal, 556 U.S. at 679. However, the court will not accept “legal conclusions couched as facts or unwarranted inferences, unreasonable conclusions, or arguments.” Nathan, 707 F.3d at 455 (quoting Wag More Dogs, LLC v. Cozart, 680 F.3d 359, 365 (4th Cir. 2012)). To determine plausibility, a court is to “draw on its judicial experience and common sense”; and if the court determines that the factual allegations can “plausibly give rise to an entitlement to relief,” dismissal is not warranted. Iqbal, 556 U.S. at 679. “But where the well-pleaded facts do not permit the court to infer more than the mere possibility of misconduct, the complaint has alleged—but it has not ‘show[n]’—‘that the pleader is entitled to relief.’” Id. (citing Fed. R. Civ. P. 8(a)(2)). DISCUSSION I. Wrongful Discharge in Violation of Public Policy

Defendant argues that Plaintiff’s first cause of action should be dismissed because Plaintiff “fails to identify a clear mandate of public policy that Bioverativ violated by terminating his employment.” ECF No. 5-1 at 4. Defendant asserts that South Carolina is a state committed to at-will employment, the narrow exception to which is available only when the discharge of an employee violates a clear mandate of public policy. Defendant contends that “[w]hile Plaintiff vaguely alleges that Titles 33 and 35 of the South Carolina Code protect shareholders and employees, Plaintiff fails to identify any provision that protects employees from termination prior to an acquisition.” Id. at 7. Defendant further contends that no such provision exists and that “Plaintiff’s vague reference to general code sections” falls short of “satisfying his obligation

to identify a clear mandate of public policy that Defendant violated.” Id. In response, Plaintiff asserts that he has sufficiently pleaded a cause of action because he alleges that Defendant “terminated his employment so as to avoid paying him stock options he would be due after the acquisition was finalized.” ECF No. 10 at 5-6. Moreover, Plaintiff asserts, the issue he raises is novel in this state and “thus, deserving of further development of facts.” Id. at 6.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
Wag More Dogs, Ltd. Liability Corp. v. Cozart
680 F.3d 359 (Fourth Circuit, 2012)
Moseley v. Oswald
656 S.E.2d 380 (Supreme Court of South Carolina, 2008)
Parrish v. Allison
656 S.E.2d 382 (Court of Appeals of South Carolina, 2007)
Rice v. Multimedia, Inc.
456 S.E.2d 381 (Supreme Court of South Carolina, 1995)
Garner v. Morrison Knudsen Corp.
456 S.E.2d 907 (Supreme Court of South Carolina, 1995)
Ludwick v. This Minute of Carolina, Inc.
337 S.E.2d 213 (Supreme Court of South Carolina, 1985)
Citizens Bank v. Gregory's Warehouse, Inc.
375 S.E.2d 316 (Court of Appeals of South Carolina, 1988)
Poole v. Incentives Unlimited, Inc.
525 S.E.2d 898 (Court of Appeals of South Carolina, 1999)
Kennedy v. Henderson
346 S.E.2d 526 (Supreme Court of South Carolina, 1986)
Craft v. South Carolina Commission for Blind
685 S.E.2d 625 (Court of Appeals of South Carolina, 2009)
Conner v. City of Forest Acres
611 S.E.2d 905 (Supreme Court of South Carolina, 2005)
Keiger v. Citgo, Coastal Petroleum, Inc.
482 S.E.2d 792 (Court of Appeals of South Carolina, 1997)
Lawson v. South Carolina Department of Corrections
532 S.E.2d 259 (Supreme Court of South Carolina, 2000)
Mathis v. Brown & Brown of South Carolina, Inc.
698 S.E.2d 773 (Supreme Court of South Carolina, 2010)
Glover v. Lockheed Corp.
772 F. Supp. 898 (D. South Carolina, 1991)
Caudle v. Thomason
942 F. Supp. 635 (District of Columbia, 1996)
White v. Roche Biomedical Laboratories, Inc.
807 F. Supp. 1212 (D. South Carolina, 1992)
Barron v. Labor Finders of SC
713 S.E.2d 634 (Supreme Court of South Carolina, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Gentry v. Bioverativ US LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gentry-v-bioverativ-us-llc-scd-2019.